Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 4/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271745 | 0.89 | HSP90AB1 (0.39) | CCNE1CDK2CDK1CCNB1POLB | |
| SCHEMBL4271693 | 0.87 | CCNE1 (0.37) | CCNE1CDK2CDK1CCNB1POLB | |
| SCHEMBL4270163 | 0.86 | CCNE1 (0.39) | CCNE1CDK2CDK1CCNB1POLB | |
| SCHEMBL4265441 | 0.85 | POLB (0.36) | CCNE1CDK2CDK1CCNB1POLB | |
| SCHEMBL4270429 | 0.85 | POLB (0.35) | CCNE1CDK2CDK1CCNB1POLB | |
| Lb80317 SCHEMBL2905773 | 0.84 | POLB (0.39) | CCNE1CDK2CDK1CCNB1POLB | |
| SCHEMBL4276470 | 0.83 | POLB (0.55) | POLB | |
| SCHEMBL2911369 | 0.78 | PNP (0.35) | CCNE1CDK2CDK1CCNB1POLB | |
| SCHEMBL3289989 | 0.77 | HPRT1 (0.39) | CCNE1CDK2CDK1CCNB1HPRT1 | |
| SCHEMBL3290871 | 0.75 | HSP90AB1 (0.40) | CCNE1CDK2CDK1CCNB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | CCNE1 1216/4885CDK2 671/4885CDK1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.